Advertisement

Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity

Published:December 23, 2022DOI:https://doi.org/10.1016/j.msard.2022.104477

      Highlights

      • Patients switching to natalizumab or fingolimod after ≥1 relapse were matched (1:1)
      • Outcomes were better for RMSS patients switching to natalizumab vs fingolimod
      • Natalizumab patients had lower relapse rates and greater time to first relapse
      • Relapse outcome differences were greatest in those with prior high-relapse activity

      Abstract

      Background

      Patients with relapsing-remitting multiple sclerosis (RRMS) who experience relapses on a first-line therapy (interferon, glatiramer acetate, dimethyl fumarate, or teriflunomide; collectively, “BRACETD”) often switch to another therapy, including natalizumab or fingolimod. Here we compare the effectiveness of switching from a first-line therapy to natalizumab or fingolimod after ≥1 relapse.

      Methods

      Data collected prospectively in the MSBase Registry, a global, longitudinal, observational registry, were extracted on February 6, 2018. Included patients were adults with RRMS with ≥1 relapse on BRACETD therapy in the year before switching to natalizumab or fingolimod. Included patients received natalizumab or fingolimod for ≥3 months after the switch.

      Results

      Following 1:1 propensity score matching, 1000 natalizumab patients were matched to 1000 fingolimod patients. Mean (standard deviation) follow-up time was 3.02 (2.06) years after switching to natalizumab and 2.58 (1.64) years after switching to fingolimod. Natalizumab recipients had significantly lower annualized relapse rate (relative risk=0.66; 95% confidence interval [CI], 0.59–0.74), lower risk of first relapse (hazard ratio [HR]=0.69; 95% CI, 0.60–0.80), and higher confirmed disability improvement (HR=1.27; 95% CI, 1.03–1.57) than fingolimod recipients. No difference in confirmed disability worsening was observed.

      Conclusions

      Patients with RRMS switching from BRACETD demonstrated better outcomes with natalizumab than with fingolimod.

      Keywords

      Abbreviations:

      ARR (annualized relapse rate), BRACETD (Betaseron, Rebif, Avonex, Copaxone, Extavia, Tecfidera, Aubagio), CI (confidence interval), DMT (disease-modifying therapy), EDSS (Expanded Disability Status Scale), HR (hazard ratio), IPTW (inverse-probability-of-treatment-weighting), MRI (magnetic resonance imaging), OFSEP (Observatoire Français de la Sclérose en Plaques), RR (relative risk), RRMS (relapsing-remitting multiple sclerosis), RRR (relapse rate ratio), SD (standard deviation)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Giovannoni G
        • Butzkueven H
        • Dhib-Jalbut S
        • et al.
        Brain health: time matters in multiple sclerosis.
        Mult Scler Relat Disord. 2016; 9: S5-S48
        • Grand'Maison F
        • Yeung M
        • Morrow SA
        • et al.
        Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.
        Neural Regen Res. 2018; 13: 1871-1874
        • Kappos L
        • Radue EW
        • O'Connor P
        • et al.
        A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
        N Engl J Med. 2010; 362: 387-401
        • Polman CH
        • O'Connor PW
        • Havrdova E
        • et al.
        A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
        N Engl J Med. 2006; 354: 899-910
        • Izquierdo G
        • Damas F
        • Paramo MD
        • Ruiz-Pena JL
        • Navarro G.
        The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
        PLoS One. 2017; 12e0176174
        • Butzkueven H
        • Kappos L
        • Pellegrini F
        • et al.
        Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
        J Neurol Neurosurg Psychiatry. 2014; 85: 1190-1197
        • Butzkueven H
        • Jeffery D
        • Arnold DL
        • et al.
        The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a randomised, head-to-head phase 4 study.
        Mult Scler. 2017; 23 ([abst P791]): 405-406
        • Kalincik T
        • Butzkueven H.
        Observational data: understanding the real MS world.
        Mult Scler. 2016; 22: 1642-1648
        • Trojano M
        • Tintore M
        • Montalban X
        • et al.
        Treatment decisions in multiple sclerosis—insights from real-world observational studies.
        Nat Rev Neurol. 2017; 13: 105-118
        • Barbin L
        • Rousseau C
        • Jousset N
        • et al.
        Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study.
        Neurology. 2016; 86: 771-778
        • Baroncini D
        • Ghezzi A
        • Annovazzi PO
        • et al.
        Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
        Mult Scler. 2016; 22: 1315-1326
        • Kalincik T
        • Horakova D
        • Spelman T
        • et al.
        Switch to natalizumab versus fingolimod in active relapsing remitting multiple sclerosis.
        Ann Neurol. 2015; 77: 425-435
        • Lorscheider J
        • Benkert P
        • Lienert C
        • et al.
        Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
        Mult Scler. 2018; 24: 777-785
        • Prosperini L
        • Sacca F
        • Cordioli C
        • et al.
        Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis.
        J Neurol. 2017; 264: 284-294
        • Carruthers RL
        • Rotstein DL
        • Healy BC
        • Chitnis T
        • Weiner HL
        • Buckle GJ.
        An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
        Mult Scler. 2014; 20: 1381-1390
        • Butzkueven H
        • Chapman J
        • Cristiano E
        • et al.
        MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.
        Mult Scler. 2006; 12: 769-774
        • Guger M
        • Enzinger C
        • Leutmezer F
        • et al.
        Real-life clinical use of natalizumab and fingolimod in Austria.
        Acta Neurol Scand. 2018; 137: 181-187
        • Lanzillo R
        • Carotenuto A
        • Moccia M
        • et al.
        A longitudinal real-life comparison study of natalizumab and fingolimod.
        Acta Neurol Scand. 2017; 136: 217-222
        • Curti E
        • Tsantes E
        • Baldi E
        • et al.
        The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study.
        Mult Scler Relat Disord. 2019; 33: 146-152
        • Andersen JB
        • Sharmin S
        • Lefort M
        • et al.
        The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies.
        Mult Scler Relat Disord. 2021; 53
        • Lefort M
        • Sharmin S
        • Andersen JB
        • et al.
        Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.
        BMC Med Res Methodol. 2022; 22: 155
        • Sharmin S
        • Lefort M
        • Andersen JB
        • et al.
        Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
        CNS Drugs. 2021; 35: 1217-1232
        • Preziosa P
        • Rocca MA
        • Riccitelli G
        • et al.
        The effects of natalizumab and fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis: a two-year comparative study.
        Eur J Neurol. 2017; 24 ([abst PR2091]): 579
        • Totaro R
        • Costantino G
        • Bellantonio P
        • et al.
        Efficacy of natalizumab and fingolimod in relapsing remitting multiple sclerosis in real world clinical setting.
        J Neurol Neurophysiol. 2015; 6: 1-6